Compare HBB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | ACIU |
|---|---|---|
| Founded | 1904 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 221.9M |
| IPO Year | 2017 | 2015 |
| Metric | HBB | ACIU |
|---|---|---|
| Price | $22.09 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 41.3K | ★ 235.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $606,852,000.00 | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | $83.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.72 | $2.03 |
| 52 Week High | $25.05 | $4.00 |
| Indicator | HBB | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 39.61 |
| Support Level | $18.15 | $2.13 |
| Resistance Level | $24.44 | $2.66 |
| Average True Range (ATR) | 1.38 | 0.12 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 43.04 | 17.00 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.